A Phase 1 Study of LY3039478 in Japanese Patients with Advanced Solid Tumors I6F-JE-JJCC

Eli Lilly Japan K.K.0 个研究点开始时间: 2016年9月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic.
•-In the judgment of the investigator, participants must be appropriate candidates for experimental therapy after available standard therapies have failed or for whom standard therapy is not appropriate.
•-Performance status of less than or equal to 1 on the Eastern Cooperative Oncology Group (ECOG) scale.
•-Adequate organ function, including hematologic, hepatic, and renal.
•-Estimated life expectancy of more than or equal to 12 weeks.

•-Received previous therapy for cancer within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agents, respectively.
•-Have serious preexisting medical conditions.
•-Have current or recent (within 3 months of study drug administration) gastrointestinal disease with chronic or intermittent diarrhea.
•-Have an active bacterial, fungal, and/or known viral infection.
•-Have known acute or chronic leukemia or current hematologic malignancies that may affect the interpretation of results.

发起方